Trial reportJournal of the American Academy of Dermatology2014
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
Trial report in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Interventions for cutaneous disease in systemic lupus erythematosus.The Cochrane database of systematic reviews · 2021Pooled it
- Drugs for discoid lupus erythematosus.The Cochrane database of systematic reviews · 2017Pooled it
- Immunotargets and Therapy for Systemic Lupus Erythematosus.ImmunoTargets and therapy · 2025Review
- Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs.Frontiers in immunology · 2022Article
- Thalidomide and discoid lupus erythematosus: case series and review of literature.Drugs in context · 2022Article
- An update on the management of refractory cutaneous lupus erythematosus.Frontiers in medicine · 2022Review
- Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.Lupus science & medicine · 2021Article
- Recent Insight on the Management of Lupus Erythematosus Alopecia.Clinical, cosmetic and investigational dermatology · 2021Review
- Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.Lupus science & medicine · 2020Review
- Cutaneous Lupus Erythematosus: Progress and Challenges.Current allergy and asthma reports · 2020Review
- Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus.Lupus science & medicine · 2020Observational
- Cutaneous lupus erythematosus: A review of the literature.International journal of women's dermatology · 2019Review
- Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.F1000Research · 2019Review
- Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study.International journal of women's dermatology · 2018Article
- Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.Lupus · 2017Article
- Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Expert review of clinical immunology · 2016Review
- Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.Dermatologic clinics · 2016Review
- [Lupus erythematosus].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.